AstraZeneca
🇬🇧United Kingdom
- Country
- 🇬🇧United Kingdom
- Ownership
- Public
- Employees
- 89.9K
- Market Cap
- $270.3B
- Website
- http://www.astrazeneca.co.uk
- Introduction
AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.
Study of Acalabrutinib in Chinese Adult Subjects With Relapsed or Refractory Mantle Cell Lymphoma, Chronic Lymphocytic Leukemia or Other B-cell Malignancies
Phase 1
Active, not recruiting
- Conditions
- Phase II Cohort A: Relapsed or Refractory Mantle Cell LymphomaPhase II Cohort B: Relapsed or Refractory Chronic Lymphocytic LeukemiaPhase I: Relapsed or Refractory B-cell Malignancies
- Interventions
- First Posted Date
- 2019-04-30
- Last Posted Date
- 2025-03-20
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 105
- Registration Number
- NCT03932331
- Locations
- 🇨🇳
Research Site, Zhengzhou, China
Prevalence of the Eosinophilic Phenotype Among Severe Asthma Patients
Completed
- Conditions
- Severe Asthma
- First Posted Date
- 2019-04-30
- Last Posted Date
- 2021-01-29
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 794
- Registration Number
- NCT03931954
- Locations
- 🇸🇦
Research Site, Riyadh, Saudi Arabia
Pharmacokinetic Study of Benralizumab in Healthy Chinese Subjects
Phase 1
Completed
- Conditions
- Healthy Subjects
- Interventions
- Biological: Benralizumab
- First Posted Date
- 2019-04-26
- Last Posted Date
- 2019-08-30
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 36
- Registration Number
- NCT03928262
- Locations
- 🇭🇰
Research Site, Hong Kong, Hong Kong
Study to Evaluate Tezepelumab in Adults With Severe Uncontrolled Asthma
Phase 3
Completed
- Conditions
- Asthma
- Interventions
- Other: Placebo
- First Posted Date
- 2019-04-25
- Last Posted Date
- 2024-08-26
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 405
- Registration Number
- NCT03927157
- Locations
- 🇵🇭
Research Site, Quezon City, Philippines
BRazilian Asthmatics Patients EOSinophilic Profile (BRAEOS)
Completed
- Conditions
- Severe Asthma
- First Posted Date
- 2019-04-24
- Last Posted Date
- 2020-08-14
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 414
- Registration Number
- NCT03925415
- Locations
- 🇧🇷
Research Site, Sorocaba, Brazil
An Exploratory Study to Characterise Changes in Airway Inflammation, Symptoms, Lung Function and Reliever Use in Adult Asthma Patients
Phase 4
Completed
- Conditions
- Airway InflammationAsthma
- Interventions
- Combination Product: SYMBICORT and salbutamol
- First Posted Date
- 2019-04-23
- Last Posted Date
- 2025-01-22
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 42
- Registration Number
- NCT03924635
- Locations
- 🇬🇧
Research Site, Wishaw, United Kingdom
Study to Assess Effect of Device and Formulation on Pharmacokinetics (PK) of AZD1402
- First Posted Date
- 2019-04-19
- Last Posted Date
- 2019-06-21
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 18
- Registration Number
- NCT03921268
- Locations
- 🇬🇧
Research Site, Harrow, United Kingdom
Korea Osimertinib Real World Evidence Study to Assess Safety and Efficacy - PLUS
Completed
- Conditions
- Carcinoma, Non-Small-Cell Lung
- First Posted Date
- 2019-04-17
- Last Posted Date
- 2024-11-25
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 923
- Registration Number
- NCT03918304
- Locations
- 🇰🇷
Research Site, Seoul, Korea, Republic of
A Clinical Trial to Evaluate AZD7648 Alone and in Combination With Other Anti-cancer Agents in Patients With Advanced Cancers.
- First Posted Date
- 2019-04-09
- Last Posted Date
- 2024-02-06
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 30
- Registration Number
- NCT03907969
- Locations
- 🇬🇧
Research Site, Newcastle upon Tyne, United Kingdom
A Scintigraphy Study of PT010 in COPD Patients
Phase 1
Completed
- Conditions
- Chronic Obstructive Pulmonary Disease
- Interventions
- Drug: BGF-MDI
- First Posted Date
- 2019-04-08
- Last Posted Date
- 2021-02-12
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 18
- Registration Number
- NCT03906045
- Locations
- 🇬🇧
Research Site, Merthyr Tydfil, United Kingdom
© Copyright 2025. All Rights Reserved by MedPath